Deep Genomics Raises $13 Million To Develop Genetic Medicines

By Bio-IT World Staff

September 25, 2017 | Deep Genomics received a USD $13 million equity investment led by Khosla Ventures. They are accompanied by early stage investment firm True Ventures.

Deep Genomics joins Khosla Ventures’ portfolio, which includes Climate Corporation, Editas Medicine, Guardant Health, and Square.

In the next three years, Deep Genomics will use its platform to unlock new classes of anti-sense oligonucleotide therapies that were previously inaccessible, and advance them for clinical evaluation. “We believe that the technology developed at Deep Genomics puts them in a unique position to identify new therapies,” said Founding Partner Vinod Khosla in a press release. “Because of the quality of their science and engineering team and the deep integration of their AI technology into their preclinical drug development pipeline, we are confident that a very large potential exists here.”

Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists, and chemists in the development of therapies.

In project Saturn, named after the god of plenty and renewal, the platform will be used to search across a vast space of over 69 billion molecules and to generate a library of 1000 compounds that can be used to precisely manipulate cell biology. This technology will enable Deep Genomics to identify preclinical candidates and to advance them for clinical evaluation in collaboration with stakeholders.